ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 145 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2015. The put-call ratio across all filers is 0.83 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,848 | -29.9% | 27,396 | -0.6% | 0.00% | – |
| Q2 2023 | $38,305 | -91.5% | 27,558 | -90.3% | 0.00% | – |
| Q1 2023 | $453,054 | -74.6% | 284,940 | -0.5% | 0.00% | – |
| Q4 2022 | $1,783,562 | -2.3% | 286,286 | +5.1% | 0.00% | – |
| Q3 2022 | $1,825,000 | +19.0% | 272,406 | +12.9% | 0.00% | – |
| Q2 2022 | $1,534,000 | +47.4% | 241,189 | +7.6% | 0.00% | – |
| Q1 2022 | $1,041,000 | +86.9% | 224,222 | +101.4% | 0.00% | – |
| Q4 2021 | $557,000 | -49.8% | 111,328 | +20.9% | 0.00% | – |
| Q3 2021 | $1,109,000 | -37.4% | 92,049 | +9.9% | 0.00% | – |
| Q2 2021 | $1,771,000 | -37.7% | 83,757 | -17.3% | 0.00% | -100.0% |
| Q1 2021 | $2,841,000 | -7.4% | 101,292 | -14.2% | 0.00% | 0.0% |
| Q4 2020 | $3,069,000 | -39.3% | 118,017 | -13.3% | 0.00% | 0.0% |
| Q3 2020 | $5,057,000 | -28.3% | 136,073 | -1.0% | 0.00% | -50.0% |
| Q2 2020 | $7,054,000 | +63.0% | 137,479 | +0.2% | 0.00% | +100.0% |
| Q1 2020 | $4,327,000 | -52.5% | 137,239 | -10.2% | 0.00% | -50.0% |
| Q4 2019 | $9,109,000 | +143.4% | 152,752 | +49.6% | 0.00% | +100.0% |
| Q3 2019 | $3,743,000 | -22.8% | 102,131 | -2.0% | 0.00% | 0.0% |
| Q2 2019 | $4,850,000 | +17.1% | 104,247 | +1.1% | 0.00% | 0.0% |
| Q1 2019 | $4,140,000 | -13.6% | 103,133 | -1.0% | 0.00% | -50.0% |
| Q4 2018 | $4,794,000 | -8.3% | 104,205 | -11.5% | 0.00% | +100.0% |
| Q3 2018 | $5,227,000 | +19.5% | 117,796 | +5.6% | 0.00% | 0.0% |
| Q2 2018 | $4,373,000 | -57.4% | 111,584 | -21.4% | 0.00% | -66.7% |
| Q1 2018 | $10,265,000 | +34.1% | 141,919 | +22.1% | 0.00% | +50.0% |
| Q4 2017 | $7,652,000 | +32.3% | 116,224 | +0.7% | 0.00% | 0.0% |
| Q3 2017 | $5,783,000 | +8.8% | 115,372 | +0.5% | 0.00% | +100.0% |
| Q2 2017 | $5,315,000 | +43.9% | 114,853 | +9.8% | 0.00% | 0.0% |
| Q1 2017 | $3,693,000 | +264.9% | 104,603 | +29.4% | 0.00% | – |
| Q4 2016 | $1,012,000 | +19.2% | 80,863 | +31.9% | 0.00% | – |
| Q3 2016 | $849,000 | +38.0% | 61,320 | -1.4% | 0.00% | – |
| Q2 2016 | $615,000 | -42.8% | 62,218 | -2.2% | 0.00% | – |
| Q1 2016 | $1,075,000 | -21.9% | 63,613 | +3.0% | 0.00% | – |
| Q4 2015 | $1,376,000 | -3.4% | 61,790 | +2.4% | 0.00% | – |
| Q3 2015 | $1,424,000 | -79.3% | 60,370 | -28.2% | 0.00% | -100.0% |
| Q2 2015 | $6,873,000 | +6.9% | 84,068 | +21.1% | 0.00% | 0.0% |
| Q1 2015 | $6,427,000 | +70.7% | 69,406 | -25.5% | 0.00% | +100.0% |
| Q4 2014 | $3,766,000 | +161.0% | 93,134 | +57.8% | 0.00% | – |
| Q3 2014 | $1,443,000 | -15.7% | 59,002 | -45.4% | 0.00% | – |
| Q2 2014 | $1,712,000 | +120.9% | 108,042 | +110.7% | 0.00% | – |
| Q1 2014 | $775,000 | +353.2% | 51,287 | +311.1% | 0.00% | – |
| Q4 2013 | $171,000 | -57.2% | 12,477 | -41.3% | 0.00% | – |
| Q3 2013 | $400,000 | – | 21,272 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |